The gentlest GH
secretagogue.
A two-peptide pairing that nudges your body's own pulsatile growth-hormone release at night. CJC-1295 sets the tone; Ipamorelin gives the pulse. Studied for sleep depth, recovery, and slow body-composition shifts — and selective enough that no cycling is required.
From$60 / month · ongoing protocolWhat CJC-1295 + Ipamorelin actually does.
The two compounds work on different sides of the same axis. CJC-1295 (modified GRF 1-29) is a long-acting analog of growth-hormone-releasing hormone — it raises the baseline at which your pituitary is ready to release GH. Ipamorelin is a selective pentapeptide ghrelin-receptor agonist that triggers the actual pulse.
Together they amplify what your body is already doing — predominantly overnight, when natural GH pulses are largest — without overriding the feedback loop. That's the reason you don't need to "cycle off" the way you would with exogenous GH.
What the human evidence shows.
The strongest evidence is for increased GH and IGF-1 levels following GHRH analog + GHRP coadministration; this is reproducible in adult human studies and forms the rationale for the protocol.
Downstream outcomes — sleep architecture, body composition, recovery — have smaller, mostly observational studies, with the largest body of work in adults with adult-onset GH deficiency. For non-deficient adults, your prescriber considers age, baseline IGF-1, and goals before recommending it.
What patients actually report.
- Sleep — week 1. Falling asleep faster; deeper "anchored" feeling overnight. Often the first noticeable change.
- Recovery — weeks 2–4. Less DOMS after the same workouts. Faster turnaround on hard training days.
- Body composition — weeks 8–12. Subtle shifts in waist measurements before the scale moves. Most patients don't see dramatic recomposition; expectations of "GH-like" changes will be disappointed.
Who CJC/Ipamorelin may be for.
- Adults 30+ with declining sleep depth — particularly the kind that doesn't respond to sleep hygiene alone.
- Recreational and competitive athletes wanting to maximize overnight recovery without exogenous hormones.
- Adults with documented adult-onset GH borderline or deficiency, in coordination with their endocrinologist.
- Patients who've tried sleep medications and want a different pathway with fewer next-day effects.
Side-effect profile.
- Tingling or transient flushing at injection (occasional, brief).
- Mild water retention in the first 1–2 weeks for a minority of patients — usually settles.
- Increased appetite in some patients — Ipamorelin works on the ghrelin receptor.
- Vivid dreams are common at first — typically settles into deeper, more consolidated sleep.
Not for use during pregnancy, with active malignancy, or in patients under 25. Patients with insulin resistance or pre-diabetes warrant additional monitoring; GH secretagogues can subtly affect insulin sensitivity over months.
How a typical Pepra protocol runs.
Standard Pepra protocol: 300 mcg combined dose, subcutaneous, taken in the evening before bed, 5 nights per week. Pulsatility — taking on/off — appears to outperform daily-7 dosing for these molecules, and the off-nights help preserve receptor sensitivity.
We re-evaluate at 8 and 16 weeks. IGF-1 lab work is recommended at the 16-week mark; many patients run the protocol continuously after that with quarterly lab refreshes.
CJC-1295 and Ipamorelin are compounded peptides, not FDA-approved finished drugs. They are sometimes confused with — and are not — recombinant human growth hormone (rHGH). The pharmacology is fundamentally different; so are the risks and the regulatory framework.
Selected references
- 1.Teichman SL, et al. "Prolonged stimulation of GH and IGF-I secretion by CJC-1295" — J Clin Endocrinol Metab. 2006;91(3):799-805.
- 2.Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue" — Eur J Endocrinol. 1998;139(5):552-561.
- 3.Sigalos JT, Pastuszak AW. "The Safety and Efficacy of Growth Hormone Secretagogues" — Sex Med Rev. 2018;6(1):45-53.
- 4.Van Cauter E, et al. "Reciprocal interactions between the GH axis and sleep" — Growth Horm IGF Res. 2004;14 Suppl A:S10-7.
- 5.Ionescu M, Frohman LA. "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295" — J Clin Endocrinol Metab. 2006;91(12):4792-7.